03:49 AM EDT, 10/06/2025 (MT Newswires) -- Abivax ( ABVX ) said Sunday that results from two clinical trials showed that a 50 milligram daily dose regimen of its potential moderate-to-severely active ulcerative colitis treatment obefazimod met its primary endpoint of clinical remission at week eight.

The company said all key secondary efficacy endpoints were also met in the trials, which enrolled 1,272 patients.

In pooled data from the trials, no signals of serious or severe infections or malignancies were observed, the company said.